Endocrine

SIADH: workup and management

Clinical Overview and When to Suspect SIADH

— ADH (vasopressin) acts on V2 receptors in collecting duct → aquaporin-2 insertion → free water retention

— Water retention dilutes serum Na⁺ without significant edema (pressure natriuresis offloads excess Na⁺)

— Result: low serum osm, inappropriately concentrated urine, mild volume expansion without overt overload

— Incidental Na⁺ <135 mEq/L on routine outpatient labs, especially in older adults

— Hospitalized patient on SSRIs, carbamazepine, cyclophosphamide, chemotherapy, or post-op pain regimens

— Small cell lung cancer, head/neck cancers (paraneoplastic ADH)

— CNS pathology: stroke, hemorrhage, meningitis, trauma, post-neurosurgery

— Pulmonary: pneumonia, TB, mechanical ventilation with positive pressure

— HIV, nausea, pain, postoperative state (transient SIADH is extremely common)

— Elderly woman on thiazide + SSRI with fall and confusion (mixed picture — thiazide is NOT pure SIADH but mimics it)

— Smoker with weight loss, hyponatremia → think SCLC

— Post-TURP or post-hysteroscopy patient with hypotonic irrigation absorption (dilutional, not true SIADH)

Board pearl: SIADH is a diagnosis of exclusion — you must first rule out hypovolemia, hypervolemia, hypothyroidism, and adrenal insufficiency before labeling a patient "SIADH." Step 3 stems often hide adrenal insufficiency or hypothyroidism behind an apparent SIADH picture, and starting fluid restriction without checking TSH and cortisol is a tested misstep.

Definition: Syndrome of Inappropriate Antidiuretic Hormone secretion — euvolemic hypotonic hyponatremia from non-physiologic ADH release with inability to dilute urine maximally.

Core physiology:

When to suspect on Step 3:

Classic patient archetypes:

Epidemiology: Most common cause of euvolemic hyponatremia in hospitalized patients; prevalence rises sharply >65.

Presentation Patterns and Key History

— Chronic (>48 h): often asymptomatic until Na⁺ <125; brain adapts via osmolyte efflux

— Acute (<48 h): seizures, obtundation, herniation possible at Na⁺ 125–130

— Mild (Na⁺ 130–134): malaise, mild cognitive slowing, gait unsteadiness, falls

— Moderate (Na⁺ 120–129): nausea, headache, confusion, lethargy

— Severe (Na⁺ <120 or rapid drop): vomiting, seizures, coma, respiratory arrest, non-cardiogenic pulmonary edema

— Medications: SSRIs (especially sertraline, citalopram), SNRIs, carbamazepine/oxcarbazepine, chemotherapy (cyclophosphamide, vincristine, cisplatin), MDMA/ecstasy, desmopressin, NSAIDs, antipsychotics

— Cancer screen: smoking history, weight loss, hemoptysis, lymphadenopathy

— Pulmonary: recent pneumonia, TB risk, ventilator

— CNS: recent stroke, trauma, surgery, headache, infection

— Endocrine: cold intolerance, weight gain, fatigue (hypothyroid); orthostasis, hyperpigmentation, salt craving (adrenal)

— Fluid intake pattern: polydipsia, marathon runners, beer potomania, tea-and-toast diet

— Recent surgery: transsphenoidal, TURP, hysteroscopy (irrigation fluids)

Step 3 management: When an ambulatory patient is found to have Na⁺ 128 on routine labs, do not reflexively admit — assess symptoms, recheck Na⁺ to confirm not pseudohyponatremia, review the med list (start a thiazide or SSRI in the last 4 weeks?), and order paired serum/urine osm and urine Na⁺ before any intervention. Asymptomatic chronic hyponatremia is managed outpatient with cause-directed therapy.

Symptom severity tracks with rate of Na⁺ drop, not absolute value:

Symptom tiers:

Targeted history checklist on Step 3:

Outpatient framing: Older patients often present with recurrent falls or "failure to thrive" — always check a BMP. Mild chronic hyponatremia increases fracture risk independent of bone density.

Physical Exam Findings (and Hemodynamic Assessment)

— Euvolemic clues (SIADH): moist mucous membranes, no edema, no JVD, no orthostasis, normal skin turgor, normal capillary refill

— Hypovolemic clues (rule out): dry mucous membranes, flat neck veins, orthostatic drop >20/10, tachycardia, decreased turgor, low urine output

— Hypervolemic clues (rule out): peripheral edema, ascites, elevated JVP, S3, pulmonary crackles, hepatomegaly

— Mental status: orientation, attention (serial 7s), drowsiness

— Gait: tandem walk — subtle ataxia is an early sign

— Reflexes, focal deficits (mimics stroke in severe cases)

— Pupillary changes, posturing → impending herniation

— Clubbing, supraclavicular node, decreased breath sounds → lung cancer

— Goiter, delayed reflexes, dry skin → hypothyroidism

— Hyperpigmentation of palmar creases, buccal mucosa → primary adrenal insufficiency

— Track marks, recent rave attendance → MDMA

— Surgical scars on neck/skull → recent neurosurgery

— BP typically normal in pure SIADH (mild volume expansion is masked)

— Hypotension or orthostasis should redirect you to hypovolemic hyponatremia or adrenal crisis

— Bradycardia + hypothermia → severe hypothyroidism mimicking SIADH

Key distinction: A patient with hyponatremia AND any orthostatic vital sign change is not euvolemic until proven otherwise — they likely have hypovolemic hyponatremia and need isotonic saline, not fluid restriction. Misclassifying a hypovolemic patient as SIADH and restricting fluids is a classic Step 3 distractor that worsens AKI and Na⁺. Always reassess volume status after initial intervention because the exam in SIADH-range volume expansion (~1–2 L) is genuinely subtle and easy to miss.

Volume status is THE pivotal exam in hyponatremia — SIADH requires euvolemia:

Neurologic exam (severity grading):

Look for clues to underlying etiology:

Vitals patterns:

Diagnostic Workup — Initial Labs

— Serum sodium — confirm with repeat draw to exclude lab error

— Serum osmolality — must be LOW (<275 mOsm/kg) for true hypotonic hyponatremia

– Normal/high serum osm with low Na⁺ = pseudohyponatremia (hyperlipidemia, hyperproteinemia) or translocational (hyperglycemia, mannitol)

– Correct Na⁺ for glucose: add ~1.6 mEq/L Na⁺ per 100 mg/dL glucose above 100

— Urine osmolality — should be >100 mOsm/kg (inappropriately concentrated) in SIADH

– Urine osm <100 → primary polydipsia, beer potomania, low solute intake (reset ADH suppressed)

— SIADH: urine Na⁺ >30–40 mEq/L (often >40) on a normal-salt diet

— Hypovolemic hyponatremia: urine Na⁺ <20 (Na⁺-avid kidneys)

— Diuretic-induced or cerebral salt wasting: urine Na⁺ high — overlap with SIADH

— TSH (rule out hypothyroidism)

— AM cortisol or cosyntropin stimulation (rule out adrenal insufficiency)

— BUN, creatinine, uric acid — SIADH classically shows low BUN, low uric acid (<4 mg/dL) due to dilution and increased urate clearance

— Glucose, lipids, total protein (pseudohyponatremia screen)

— Hypotonic hyponatremia, urine osm >100, urine Na⁺ >30, euvolemia, normal thyroid/adrenal/renal/cardiac/hepatic function, no recent diuretics

CCS pearl: Order "Serum osm, urine osm, urine Na, urine Cr, TSH, cortisol, glucose, lipid panel" as a bundle on day 0 — Step 3 CCS rewards parallel ordering of the full diagnostic set rather than sequential reactive testing.

Confirm true hypotonic hyponatremia first (3-step osmolality check):

Urine sodium:

Required exclusions before calling it SIADH:

Additional baseline: CMP, urinalysis, urine creatinine (for FE calculations if mixed picture suspected)

Schwartz–Bartter criteria (classic SIADH diagnostic criteria):

Diagnostic Workup — Advanced and Etiology-Specific

— Imaging chest: CXR first; low-dose CT chest if smoker or unexplained — screen for small cell lung cancer (paraneoplastic ADH is a classic cause)

— CT/MRI head: if any neurologic symptoms, headache, focal findings, recent trauma, or unexplained SIADH — looks for stroke, mass, SAH, hydrocephalus

— MRI brain with pituitary protocol if concurrent endocrine abnormalities

— Both have hyponatremia, high urine Na⁺, high urine osm

— CSW: hypovolemic (negative salt and water balance) — orthostasis, low CVP, polyuria, weight loss

— SIADH: euvolemic (water retention) — no orthostasis, normal/slightly increased weight

— Context: CSW classically after SAH, TBI, neurosurgery

— Treatment diverges: CSW needs salt and volume (often hypertonic saline + fludrocortisone); SIADH needs fluid restriction — getting this wrong is dangerous

— Carbamazepine, oxcarbazepine, SSRIs, SNRIs, antipsychotics, cyclophosphamide, MDMA, vincristine, opioids, PPIs (mild association), thiazides (NOT true SIADH but very common mimic)

— Type A: erratic ADH release (paraneoplastic) — ~30%

— Type B: constant ADH release — ~30%

— Type C: reset osmostat — ADH responds to a lower threshold (chronic, mild Na⁺ 125–135, no treatment needed)

— Type D: NSIAD — gain-of-function V2 receptor mutation, ADH low

Board pearl: A reset osmostat patient maintains a stable, low Na⁺ (often 128–133) without symptoms and normally excretes a water load. Recognize it to avoid futile fluid restriction — pregnancy, malnutrition, quadriplegia, and chronic psychiatric illness are typical settings.

Identify the SIADH cause — required before chronic management:

Distinguishing SIADH from cerebral salt wasting (CSW):

Copeptin (surrogate for ADH) — not routinely required but emerging in nephrogenic syndrome of inappropriate antidiuresis (NSIAD) workup and differentiating polyuria etiologies

Water-loading test: historical, rarely done now — risky in symptomatic patients

Drug-induced workup:

Subtypes of SIADH (Robertson classification):

Risk Stratification and Management Triage

— Severe symptoms (seizure, coma, vomiting, respiratory distress): treat NOW with hypertonic saline regardless of chronicity

— Moderate symptoms (headache, confusion, gait instability): hypertonic saline if Na⁺ <125 or symptomatic

— Mild/asymptomatic chronic: fluid restriction ± oral salt/urea; treat underlying cause

— Chronic (>48 h or unknown duration): brain has adapted — rapid correction → ODS (central pontine myelinolysis)

— Acute (<48 h, documented): brain has not adapted — can correct faster, lower ODS risk

— Maximum 8 mEq/L in any 24-hour period in patients at risk for ODS

— 6 mEq/L/24h if high ODS risk: Na⁺ <105, alcoholism, malnutrition, hypokalemia, advanced liver disease

— Target initial rise of 4–6 mEq/L in the first 6 hours to halt symptoms — then plateau

— Na⁺ <120 or symptomatic → admit, often ICU/step-down for q2h Na⁺ checks

— Na⁺ 120–129 asymptomatic → admit floor, address cause

— Na⁺ ≥130 chronic asymptomatic → outpatient workup acceptable if reliable follow-up

Step 3 management: If Na⁺ overcorrects beyond the 8 mEq/24h limit, re-lower with D5W ± desmopressin (DDAVP 2–4 mcg IV) to bring Na⁺ back down. This "DDAVP clamp" strategy — giving DDAVP prophylactically with hypertonic saline in high-risk patients — is increasingly favored and is tested. Recognize that overcorrection is the real enemy, not slow correction.

Stratify by symptom severity AND chronicity — these dictate intervention pace:

Chronicity matters because of osmotic demyelination syndrome (ODS) risk:

Correction rate limits (memorize):

Initial Na⁺ rise goal in symptomatic severe hyponatremia: 4–6 mEq/L → resolves seizures and herniation risk without breaching ODS threshold

Disposition triage:

Stop the offending agent immediately when identified (SSRI, thiazide, carbamazepine)

Pharmacotherapy — First-Line Regimens

— 3% hypertonic saline 150 mL IV bolus over 10 min, may repeat ×2 until symptoms resolve or Na⁺ rises 4–6 mEq/L

— Alternative: 100 mL boluses ×3 q10min

— Check Na⁺ every 2 hours initially

— Stop hypertonic saline once symptoms resolve or 6 mEq/L rise achieved

— 3% saline at 0.5–1 mL/kg/hr continuous infusion with q2–4h Na⁺ monitoring

— Or intermittent boluses as above

— Step 1: Fluid restriction to 800–1000 mL/day (or <500 mL below 24-h urine output)

– Predict failure of restriction: urine osm >500, urine Na⁺ + K⁺ > serum Na⁺ (Furst ratio >1), 24-h urine volume <1.5 L

— Step 2: Oral salt tablets ± loop diuretic (furosemide 20–40 mg/day reduces urine concentration ability)

— Step 3: Urea 15–60 g/day PO — induces osmotic diuresis; safe, cheap, increasingly first-line in Europe

— Step 4: Vasopressin receptor antagonists (vaptans)

– Tolvaptan (oral V2 antagonist) — initiate inpatient due to overcorrection risk; FDA caps duration ≤30 days due to hepatotoxicity; contraindicated in liver disease

– Conivaptan IV (V1a/V2) — inpatient only, 4-day max

– Liberalize fluids when on vaptan to prevent overcorrection

Board pearl: Calculate sodium deficit using Adrogue–Madias formula, but trust frequent direct Na⁺ measurements over formulas — they systematically underestimate the rise. Recheck Na⁺ q2h during hypertonic saline and adjust in real time.

Severe symptomatic (seizure, coma, Na⁺ <120 acute):

Moderate symptoms:

Chronic asymptomatic SIADH — stepwise outpatient therapy:

Demeclocycline: rarely used now (nephrotoxic, slow onset) — superseded by vaptans/urea

Treat the cause: discontinue SSRI, resect SCLC, treat pneumonia, replace cortisol/thyroid

Expanded Pharmacology and Procedural Considerations

— 3% NaCl = 513 mEq Na⁺/L; central line preferred for prolonged infusion but boluses can go peripherally in emergencies

— Co-administer loop diuretic if concurrent volume overload concern (rare in pure SIADH)

— Monitor: serum Na⁺ q2h, urine output hourly (a sudden water diuresis = ADH "turned off" → overcorrection imminent → give DDAVP)

— DDAVP 2 mcg IV q8h + 3% saline titrated to controlled Na⁺ rise

— Eliminates unpredictable aquaresis when underlying cause resolves

— Strongly considered for Na⁺ <120 with high ODS risk

— Start 15 mg PO daily, titrate to 30–60 mg

— Must initiate inpatient without fluid restriction during first 24–48 h

— Monitor LFTs; stop if ALT >3× ULN

— Avoid CYP3A4 inhibitors (ketoconazole, clarithromycin)

— Cost and hepatotoxicity make urea more attractive long-term

— Treat underlying tumor (SCLC chemo/radiation often resolves paraneoplastic SIADH)

— Drain CNS lesions, treat infection source

— Isotonic saline in pure SIADH can paradoxically worsen hyponatremia if urine osm > infusate osm (urine osm >308 mOsm/kg) — kidneys retain free water, excrete Na⁺

— D5W in symptomatic hyponatremia — exacerbates the problem

CCS pearl: In CCS-style cases, after starting 3% saline write standing orders for "serum Na q2h, neuro checks q2h, strict I/Os, urine output q1h." Advance the clock 2 hours, reassess, and titrate. Skipping monitoring orders or advancing time too aggressively is a graded action.

Hypertonic saline practicalities:

DDAVP clamp protocol (proactive overcorrection prevention):

Tolvaptan dosing:

Urea practical use: mix in juice to mask taste; 15–30 g/day typical maintenance; works via osmotic diuresis without ODS overcorrection risk

Salt tablets: 1–3 g NaCl PO TID adjunct; useful with low-dose furosemide

Procedures in SIADH context:

What NOT to give:

Special Populations — Elderly and Renal/Hepatic Impairment

— Age-related reduction in renal free-water excretion + polypharmacy

— Thiazides + SSRIs are the most common iatrogenic combo

— Even mild chronic hyponatremia (Na⁺ 130–134) → falls, fractures, osteoporosis, cognitive impairment, increased mortality

— Always check Na⁺ in any older patient with a fall, new confusion, or "failure to thrive"

— Start fluid restriction conservatively (1–1.2 L); strict <800 mL is poorly tolerated and worsens dehydration risk

— Reduced free-water excretion baseline → SIADH-like picture without true SIADH

— Loop diuretics + salt may help; vaptans less effective as GFR <30 mL/min

— Urea is safe and effective across CKD stages

— Hyponatremia is hypervolemic (high ADH driven by effective arterial underfilling) — NOT SIADH despite similar lab pattern

— Tolvaptan contraindicated in cirrhosis (FDA black box: hepatotoxicity, hepatic failure)

— Manage with fluid restriction, albumin, treat portal hypertension; avoid vaptans

— Higher ODS risk — cap correction at 6 mEq/24h

— Hypervolemic hyponatremia, not SIADH — treat with diuresis, sodium restriction, GDMT

— Tolvaptan modestly effective for symptomatic hyponatremia in HF; short-term use only

Key distinction: In cirrhosis and CHF, hyponatremia is a marker of disease severity, not SIADH. Treat the underlying hemodynamics — diuretics, vasopressors, transplant evaluation — rather than applying SIADH algorithms. ODS risk is highest in these populations, especially malnourished alcoholics with K⁺ <3, so cap correction at 6 mEq/24h and consider proactive DDAVP clamping.

Elderly (>65) — disproportionately affected:

CKD:

Cirrhosis:

Heart failure:

Hepatic adjustment: Carbamazepine, oxcarbazepine cleared hepatically — accumulate and worsen SIADH; check levels

Special Populations — Pregnancy, Pediatrics, Athletes

— Normal pregnancy resets osmostat ~5 mOsm lower → baseline Na⁺ often 130–135 (physiologic, not SIADH)

— True SIADH rare; consider HELLP, preeclampsia, hyperemesis-related hypovolemia

— Vaptans contraindicated in pregnancy and lactation

— Manage with mild fluid restriction; correct slowly

— Common causes: meningitis, pneumonia, head trauma, post-op (especially after spinal fusion, tonsillectomy)

— Hypotonic maintenance IV fluids cause hospital-acquired hyponatremia — current standard is isotonic maintenance fluids (0.9% NS or LR) for hospitalized children (AAP 2018)

— Symptoms manifest at higher Na⁺ in children due to smaller brain–skull ratio reserve

— Hypertonic saline 3% at 2–5 mL/kg bolus for symptomatic children

— Marathons, ironman events, military recruits

— Pathophysiology: excess hypotonic fluid intake + non-osmotic ADH release from exercise stress

— Can be fatal (cerebral edema)

— Treatment: 3% saline 100 mL boluses even in field settings if severe symptoms

— Prevention: drink to thirst, not on a schedule

— Combination of ADH release + excessive water intake at raves

— Young women particularly susceptible

— Hypertonic saline + supportive care

— Pain, nausea, opioids, and hypotonic IV fluids combine — most common iatrogenic SIADH setting

— Switch maintenance fluids to isotonic; control pain/nausea

Step 3 management: For any hospitalized adult or child requiring maintenance IV fluids, default to isotonic crystalloid (LR or 0.9% NS) rather than D5½NS — this single practice change has cut hospital-acquired hyponatremia rates substantially and is increasingly tested.

Pregnancy:

Pediatrics:

Endurance athletes — exercise-associated hyponatremia (EAH):

MDMA (ecstasy) users:

Postoperative patients:

Complications and Adverse Outcomes

— Seizures, coma, brainstem herniation, non-cardiogenic pulmonary edema, death

— Highest risk: premenopausal women, children, marathon runners (less brain-skull room)

— Iatrogenic complication from overly rapid correction of chronic hyponatremia

— Pathophysiology: brain osmolytes can't re-accumulate fast enough → demyelination in pons, basal ganglia, thalamus

— Highest risk: chronic Na⁺ <120, alcoholism, malnutrition, hypokalemia, advanced liver disease

— Clinical course: initial improvement post-correction → 2–6 days later develops dysarthria, dysphagia, spastic quadriparesis, "locked-in" syndrome, seizures, coma

— Diagnosis: MRI shows symmetric pontine/extrapontine demyelination — may lag clinical findings by 1–2 weeks

— Treatment: largely supportive; some recover partially; many have permanent deficits

— Prevention is the only effective intervention — limit correction to ≤8 mEq/24h, ≤6 mEq/24h in high-risk

— Gait instability and falls (subtle ataxia)

— Osteoporosis and fractures (independent of bone density)

— Cognitive impairment

— Increased all-cause mortality

— Tolvaptan: hepatotoxicity, rapid overcorrection, thirst

— Hypertonic saline extravasation: tissue necrosis (prefer central line for prolonged use)

— Demeclocycline: photosensitivity, nephrotoxicity

— Fluid restriction: dehydration, AKI in elderly

Board pearl: A patient who improves neurologically after Na⁺ correction and then deteriorates 2–6 days later with dysarthria and quadriparesis has ODS until proven otherwise — and the answer to "what should have been done?" is correction at ≤8 mEq/24h, not the technique used. Re-lowering Na⁺ with D5W ± DDAVP within 24 hours of overcorrection can prevent ODS even retroactively.

Acute hyponatremia complications (cerebral edema):

Osmotic demyelination syndrome (ODS) — formerly central pontine myelinolysis:

Chronic mild hyponatremia complications (often overlooked):

Treatment-related complications:

When to Escalate — ICU, Consult, Inpatient Triage

— Seizures, obtundation, coma, respiratory failure

— Na⁺ <120 acute or symptomatic

— Need for q2h sodium monitoring with active hypertonic saline infusion

— Hemodynamic instability or concurrent adrenal crisis

— Na⁺ 120–129 with mild symptoms

— Need for IV therapy or close monitoring not requiring ICU

— Inability to maintain reliable fluid restriction at home

— Initiation of tolvaptan (FDA mandate to start in hospital)

— Na⁺ ≥130, asymptomatic, chronic, identified reversible cause

— Reliable patient with timely follow-up (within 1 week) and BMP recheck

— Nephrology — Na⁺ <125, failed first-line therapy, vaptan candidacy, mixed picture (CSW vs SIADH), diagnostic uncertainty

— Endocrinology — concurrent pituitary disease, suspected adrenal insufficiency, reset osmostat workup

— Oncology — paraneoplastic SIADH (SCLC) management

— Neurosurgery — post-op SIADH vs CSW after SAH/TBI

— Toxicology — drug-induced (MDMA, lithium-mediated)

— Community hospital without q2h lab turnaround → transfer for severe hyponatremia

— Need for tolvaptan initiation if local pharmacy doesn't stock

— Symptomatic resolution

— Na⁺ trending up at safe rate (not exceeding 8 mEq/24h)

— Stable on chosen chronic therapy (fluid restriction, urea, salt tabs)

— Underlying cause addressed or follow-up plan in place

— Patient understands fluid restriction and warning signs

CCS pearl: A "consult nephrology" order in CCS is rewarded when ordered early for Na⁺ <120 or when overcorrection occurs — don't wait for full diagnostic workup. Pair with continued direct management; consults augment, they don't replace your action.

ICU admission criteria:

Floor admission criteria:

Outpatient management acceptable:

Consultations:

Transfer considerations:

Discharge criteria:

Key Differentials — Other Causes of Hypotonic Hyponatremia

— Hypothyroidism: severe (myxedema) reduces free-water excretion; check TSH on every case

— Adrenal insufficiency (secondary or glucocorticoid deficiency): cortisol deficiency → unopposed ADH; high-dose glucocorticoid trial both diagnostic and therapeutic

— Primary polydipsia: psychiatric patients, excessive water intake; urine osm <100 (kidneys appropriately dilute), urine Na⁺ low/variable

— Beer potomania / tea-and-toast syndrome: low solute intake → can't excrete free water despite suppressed ADH; urine osm low; treat with adequate protein/salt intake

— Reset osmostat: stable mild hyponatremia, normal water-load response — no treatment

— Exercise-associated hyponatremia: athletes; overdrinking

— Drug-induced "true" SIADH: SSRIs, carbamazepine, cyclophosphamide

— Step 1: Serum osm → low confirms hypotonic

— Step 2: Urine osm → <100 = water excess (polydipsia, low solute) vs >100 = ADH effect

— Step 3: Volume status → euvolemic vs hypo/hypervolemic

— Step 4: Urine Na⁺ → directs further workup

— Step 5: TSH, cortisol → rule out endocrine

— Cortisol deficiency mimics SIADH perfectly; suspect with hypotension, hypoglycemia, hyperkalemia, eosinophilia

— Hypothyroidism: bradycardia, hypothermia, delayed reflexes

— Both must be excluded before diagnosing SIADH

Key distinction: Urine osm <100 rules out SIADH and points to primary polydipsia or low-solute states. Urine osm >100 with urine Na⁺ >30 and euvolemia with normal TSH/cortisol is the textbook SIADH lab signature. The single most diagnostically discriminating test is paired serum and urine osmolality measured simultaneously.

Same-category (euvolemic hypotonic) hyponatremia:

Differentiation algorithm:

Endocrine masqueraders:

Key Differentials — Hypovolemic and Hypervolemic Hyponatremia

— Renal losses (urine Na⁺ >20):

– Thiazide diuretics (classic — elderly woman on HCTZ presenting with Na⁺ 118)

– Mineralocorticoid deficiency (Addison)

– Cerebral salt wasting (post-SAH/TBI)

– Salt-wasting nephropathy

— Extrarenal losses (urine Na⁺ <20):

– GI: vomiting, diarrhea, NG suction

– Skin: burns, profuse sweating

– Third-spacing: pancreatitis, peritonitis

— Treatment: isotonic saline — correct volume deficit, ADH suppression follows

— CHF

— Cirrhosis

— Nephrotic syndrome

— Advanced CKD (reduced free-water excretion)

— Treatment: fluid + sodium restriction, diuretics, treat underlying organ failure

— Mimics SIADH (urine Na⁺ high, urine osm high, often clinically euvolemic)

— But is actually mildly hypovolemic

— Stop thiazide → Na⁺ usually corrects rapidly (watch for ODS risk if drops over 48 h)

— Don't substitute another thiazide; consider ACEi, CCB, ARB

— Cirrhotic on SSRI on diuretic on low-solute diet — pick apart contributors

— Elderly patient with pneumonia (SIADH trigger) + nausea + low intake (hypovolemic component)

Step 3 management: When uncertain whether hyponatremia is SIADH or hypovolemic, a diagnostic 0.5–1 L isotonic saline challenge can help — Na⁺ rises in hypovolemic states; Na⁺ falls or stays the same (or paradoxically worsens) in SIADH. Use cautiously and reassess at 4–6 hours.

Hypovolemic hyponatremia (low total body Na⁺ AND water, Na⁺ loss > water loss):

Hypervolemic hyponatremia (high total body Na⁺ and water, water > Na⁺):

Thiazide-induced hyponatremia (critical distinction):

Mixed pictures:

Secondary Prevention and Long-Term Plan

— Discontinue or substitute offending drug:

– SSRI → consider mirtazapine, bupropion (lower hyponatremia risk)

– Carbamazepine → levetiracetam or lamotrigine

– Thiazide → ACEi/ARB, CCB, or chlorthalidone alternative discussion (similar risk)

– Avoid rechallenge with the same agent

— Treat malignancy: chemotherapy/radiation for SCLC; resect head/neck cancer

— Treat pulmonary or CNS infection; resolve usually resolves SIADH within days–weeks

— Replace cortisol, thyroid hormone if applicable

— Fluid restriction 800–1200 mL/day (sustainable level)

— Add salt tabs 1–3 g TID + low-dose furosemide 20 mg/day

— Urea 15–30 g/day (cheap, effective, ODS-safe)

— Tolvaptan as last resort (cost, hepatotoxicity, 30-day FDA cap on duration)

— Recognize symptoms: confusion, headache, gait change, nausea

— Daily weights if on tolvaptan or urea (sudden weight loss = water diuresis)

— Avoid free water excess; understand "fluid restriction" includes all liquids (coffee, soup, ice cream)

— Medication list review with every visit — avoid SSRIs, NSAIDs (potentiate ADH), thiazides, MDMA

— Pneumococcal and influenza vaccines (pneumonia is a common SIADH trigger)

— Aggressive smoking cessation if SCLC risk

Board pearl: Patients with drug-induced SIADH usually normalize within 1–2 weeks of stopping the offending agent. If hyponatremia persists beyond that, search for a second cause — patients can have two reasons for hyponatremia simultaneously, and Step 3 stems exploit this layered pathophysiology.

Address the underlying cause — primary prevention of recurrence:

Chronic SIADH (idiopathic or unresolvable cause) maintenance therapy ladder:

Patient education:

Vaccinations and comorbid care:

Follow-Up, Monitoring, and Counseling

— Within 1 week of discharge, then every 1–2 weeks until stable on chronic therapy, then every 3–6 months

— If new fluid restriction or medication started: BMP at 1 week, 2 weeks, 1 month, then quarterly

— LFTs at baseline, 2 weeks, 4 weeks, then monthly for 18 months, then quarterly

— Stop if ALT >3× ULN

— Maximum 30-day initial course; reassess need

— BMP and BUN at 1, 2, 4 weeks then quarterly

— Adjust dose based on Na⁺ trend

— Primary care quarterly

— Endocrinology or nephrology biannually if complex chronic SIADH

— Oncology surveillance if paraneoplastic

— Fluid restriction strategy: measure daily intake, use a marked container, count ALL liquids

— Symptom diary: track headache, gait changes, nausea

— Medication reconciliation: bring all bottles to every visit; alert any prescriber to SIADH history

— Dietary salt: maintain normal (not low) sodium intake unless cirrhotic/CHF

— Avoid extreme exercise without electrolyte replacement (athletes)

— Patients with prior severe hyponatremia and falls — assess gait, consider PT/OT referral

— Driving restrictions if seizure occurred until evaluated by neurology (state-dependent)

— Avoid unnecessary thiazides in elderly with prior hyponatremia

— Document fluid restriction adherence

Step 3 management: For an elderly patient discharged after thiazide-induced hyponatremia, the discharge plan must include (1) thiazide discontinuation with alternative antihypertensive, (2) BMP in 5–7 days, (3) clear instruction not to restart the thiazide, and (4) a written med list given to the patient and PCP — transition-of-care failures here cause readmissions and are increasingly tested.

Post-discharge BMP cadence:

Tolvaptan-specific monitoring:

Urea therapy monitoring:

Outpatient follow-up clinics:

Counseling points:

Driving/safety counseling:

Quality measures:

Ethical, Legal, and Patient Safety Considerations

— Standardized order sets for hypertonic saline with mandatory q2h Na⁺ checks

— Pharmacy double-check of 3% NaCl orders

— Smart pump dose limits

— Closed-loop communication when shift changes during active correction (handoff is a high-risk moment for missed lab checks → overcorrection → ODS)

— Tolvaptan: requires explicit counseling about hepatotoxicity (FDA REMS-like documentation); patient must understand 30-day limit

— Hypertonic saline in altered patients: presumed consent under emergency doctrine when life-threatening; document

— Patients with severe hyponatremia who refuse hospitalization (capacity assessment — confusion from hyponatremia itself may impair capacity, justifying urgent treatment under implied consent if life-threatening)

— Discharging a patient on continued offending agent (e.g., SSRI not stopped) = recurrence guaranteed

— Failing to communicate hyponatremia history to PCP and pharmacy

— Tolvaptan started inpatient must be reconciled at discharge; insurance prior auth needed; never send without LFT plan

— Suspected MDMA-related hyponatremia in a minor — child protective considerations

— Mass-casualty exercise events (marathon, military) — public health reporting in some jurisdictions

— ODS from overcorrection — extensively litigated; meticulous documentation of correction rate and rationale is protective

— Missed adrenal insufficiency labeled as SIADH — treated with fluid restriction → adrenal crisis

— In terminal SCLC with refractory SIADH, aggressive treatment may not align with goals; integrate palliative care early

— Discuss with patient/family whether to pursue tolvaptan vs comfort-focused approach

CCS pearl: Explicitly documenting the goal correction rate ("target Na⁺ rise ≤8 mEq/24h, ≤6 mEq/24h given malnutrition") at the time hypertonic saline is started is both good care and medicolegally protective — and Step 3 vignettes reward the candidate who frames management decisions in terms of explicit safety targets.

Patient safety — the #1 SIADH safety issue is overcorrection:

Informed consent edge cases:

Transition-of-care risks:

Mandatory reporting:

Litigation hotspots:

Ethics — end-of-life:

High-Yield Associations and Rapid-Fire Facts

— SSRIs (sertraline, citalopram — #1 outpatient culprit)

— Carbamazepine, oxcarbazepine (highest of antiepileptics)

— Cyclophosphamide, vincristine, cisplatin, vinblastine

— MDMA (ecstasy)

— Desmopressin (DDAVP) — direct ADH analog

— Antipsychotics (haloperidol, phenothiazines)

— Opioids, NSAIDs (potentiate ADH)

— Nicotine — acute increases ADH

— Small cell lung cancer (paraneoplastic — classic)

— Head and neck squamous cell carcinoma

— Olfactory neuroblastoma

— Mesothelioma, GI cancers (less common)

— Pneumonia (bacterial, viral, Legionella, TB)

— Aspergillosis

— Mechanical ventilation, especially PEEP

— Cystic fibrosis exacerbation

— Stroke, SAH, ICH

— Meningitis, encephalitis, brain abscess

— Head trauma, post-neurosurgery

— Multiple sclerosis, Guillain–Barré, acute psychosis

— Hydrocephalus

— Na⁺ <135, serum osm <275, urine osm >100, urine Na⁺ >30

— Low BUN (<10), low uric acid (<4), low albumin (dilution)

— Normal K⁺, normal creatinine, normal acid-base

— Schwartz–Bartter criteria — diagnostic

— Adrogue–Madias formula — Na⁺ deficit calculation

— Furst ratio — (urine Na⁺ + K⁺)/serum Na⁺ >1 predicts fluid restriction failure

— Smoker + weight loss + hyponatremia = SCLC

— Elderly + thiazide + SSRI + fall = drug-induced euvolemic hyponatremia

— Post-marathon + seizure = EAH → 3% saline now

Board pearl: Uric acid <4 mg/dL is the most underused discriminator — it points strongly to SIADH (and away from hypovolemic states where uric acid is high). Persistently elevated uric acid after Na⁺ correction suggests CSW rather than SIADH.

Drugs causing SIADH (memorize):

Cancers causing SIADH:

Pulmonary causes:

CNS causes:

Classic lab signature:

Eponyms and equations:

"Don't miss" combos:

Board Question Stem Patterns

— Stem: 72-yo woman on sertraline started 3 weeks ago for depression, found confused with Na⁺ 122, urine osm 480, urine Na⁺ 55, euvolemic exam, TSH and cortisol normal

— Answer: discontinue sertraline + fluid restriction; not hypertonic saline unless seizing

— Stem: 65-yo smoker with weight loss, Na⁺ 124, hyponatremia workup consistent with SIADH

— Next step: CT chest looking for SCLC

— Stem: post-marathon runner found seizing, Na⁺ 118

— Answer: 3% saline 100–150 mL bolus IV stat, repeat as needed; target 4–6 mEq/L rise to abort seizure

— Stem: chronic alcoholic with Na⁺ 108, started on hypertonic saline, Na⁺ rises to 122 in 18 hours, now developing dysarthria 4 days later

— Diagnosis: ODS; prevention answer: cap correction at 6 mEq/24h; rescue answer if caught early: D5W + DDAVP to re-lower

— Stem: post-SAH day 5 with Na⁺ 128, orthostatic, weight down 3 kg, urine output high, urine Na⁺ 80

— Diagnosis: CSW, not SIADH → isotonic saline + fludrocortisone, NOT fluid restriction

— Stem: multiple myeloma patient with Na⁺ 128 but serum osm 290

— Answer: pseudohyponatremia from hyperproteinemia; no treatment

— Stem: quadriplegic with chronic stable Na⁺ 131, asymptomatic, normal workup

— Answer: no treatment; observe

— Stem: elderly woman on HCTZ with Na⁺ 119, urine Na⁺ 45, urine osm 380

— Answer: stop HCTZ; cautious volume + monitor for autocorrection (ODS risk if drops too fast)

Key distinction: Step 3 frequently tests the management sequence — recognize SIADH features, then ask "What's the cause?" then "What's the correct rate-limited treatment?" Memorizing the lab pattern alone is insufficient; you must execute the algorithm step by step.

Pattern 1 — Drug-induced SIADH:

Pattern 2 — Paraneoplastic SIADH:

Pattern 3 — Severe symptomatic hyponatremia:

Pattern 4 — Overcorrection / ODS risk:

Pattern 5 — Post-SAH differentiation:

Pattern 6 — Pseudohyponatremia:

Pattern 7 — Reset osmostat:

Pattern 8 — Thiazide hyponatremia masquerading as SIADH:

One-Line Recap

SIADH is euvolemic hypotonic hyponatremia from inappropriate ADH release — diagnosed by paired osms (serum <275, urine >100), urine Na⁺ >30, and excluded hypothyroidism/adrenal insufficiency — and treated by addressing the underlying cause plus rate-limited correction (≤8 mEq/24h, ≤6 in high-risk) using hypertonic saline for severe symptoms, fluid restriction first-line for chronic disease, and urea or tolvaptan for refractory cases, while obsessively avoiding overcorrection that causes osmotic demyelination.

Board pearl: The single highest-yield Step 3 SIADH question tests whether you remember to rule out adrenal insufficiency and hypothyroidism before fluid-restricting — order TSH and cortisol on every hyponatremia workup, every time.

Diagnostic triad: low serum osm + inappropriately high urine osm + urine Na⁺ >30 in euvolemic patient with normal TSH/cortisol; low BUN and uric acid <4 support the diagnosis.

Correction rate is sacred: never exceed 8 mEq/L in 24 hours (6 if malnourished, alcoholic, hypokalemic, Na⁺ <105, cirrhotic); recheck Na⁺ every 2 hours during active therapy; use DDAVP clamp or D5W rescue if overcorrecting.

Cause-directed therapy wins: stop SSRIs/carbamazepine/thiazides, treat pneumonia or SCLC, replace cortisol/thyroid — most SIADH resolves when the trigger is removed; chronic refractory cases get fluid restriction → urea/salt+furosemide → tolvaptan (inpatient initiation, hepatotoxicity, 30-day cap).

Don't get fooled: thiazides mimic SIADH but are hypovolemic; cerebral salt wasting after SAH is hypovolemic and needs salt + volume, not restriction; cirrhosis/CHF hyponatremia is hypervolemic; reset osmostat needs no treatment; pseudohyponatremia has normal serum osm.